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Abstract
Background: Acid suppression with a proton pump inhibitor is standard treatment for gastroesophageal reflux disease 
and erosive esophagitis in adults and increasingly is becoming first-line therapy for children aged 1-17 years. We 
evaluated endoscopic healing of erosive esophagitis with esomeprazole in young children with gastroesophageal 
reflux disease and described esophageal histology.
Methods: Children aged 1-11 years with endoscopically or histologically confirmed gastroesophageal reflux disease 
were randomized to esomeprazole 5 or 10 mg daily (< 20 kg) or 10 or 20 mg daily (≥ 20 kg) for 8 weeks. Patients with 
erosive esophagitis underwent an endoscopy after 8 weeks to assess healing of erosions.
Results: Of 109 patients, 49% had erosive esophagitis and 51% had histologic evidence of reflux esophagitis without 
erosive esophagitis. Of the 45 patients who had erosive esophagitis and underwent follow-up endoscopy, 89% 
experienced erosion resolution. Dilation of intercellular space was reported in 24% of patients with histologic 
examination.
Conclusions: Esomeprazole (0.2-1.0 mg/kg) effectively heals macroscopic and microscopic erosive esophagitis in this 
pediatric population with gastroesophageal reflux disease. Dilation of intercellular space may be an important 
histologic marker of erosive esophagitis in children.
Trial Registration: D9614C00097; ClinicalTrials.gov identifier NCT00228527.
Background
Gastroesophageal reflux disease (GERD) increasingly is
recognized in young children. A recent retrospective
population-based cohort study in Rochester, MN, found
that the incidence of GERD in children aged < 5 years was
0.9/1,000 person-years [1]. Data on the prevalence and
severity of erosive esophagitis (EE) in young children are
limited. The prevalence of endoscopy- and biopsy-proven
EE in one study was 29% in 209 patients with GERD aged
18 months to 10 years who had no neurologic abnormali-
ties or congenital esophageal anomalies [2]. A retrospec-
tive review of the Pediatric Endoscopy Database System-
Clinical Outcomes Research Initiative (PEDS-CORI)
demonstrated that, of 7,188 children aged ≤ 18 years who
underwent endoscopy, 12.4% had EE [3].
Although endoscopy is a valuable tool in the diagnosis
of pediatric GERD and EE that provides macroscopic evi-
dence of erosions, histology is important because abnor-
malities may be present without visible lesions on
endoscopy. The North American Society for Pediatric
Gastroenterology, Hepatology, and Nutrition
(NASPGHAN) guidelines for pediatric GERD recom-
mend esophageal biopsy in conjunction with diagnostic
endoscopy [4]. If erosions are identified, histology is not
considered mandatory for routine diagnosis of GERD. On
histology, esophagitis is diagnosed by the presence of epi-
thelial hyperplasia, intraepithelial inflammation, vascular
dilatation in papillae, balloon cells, and ulceration [5].
Dilated intercellular spaces have been described as an
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additional morphologic feature of GERD and esophagitis
in infancy and childhood [6]. Mucosal biopsies also are
recommended but not mandatory in current pediatric
endoscopy practice to exclude potentially confounding
diagnoses, such as eosinophilic or infectious esophagitis
and, less commonly, Barrett's esophagus [4].
Acid suppression with a proton pump inhibitor (PPI) is
standard treatment for GERD and EE in adults [7] and
increasingly is becoming first-line therapy for children
aged 1-17 years [4]. Currently three PPIs are approved by
the US Food and Drug Administration for the treatment
of EE in children: esomeprazole (1-17 years), omeprazole
(2-16 years), and lansoprazole (1-17 years). Findings from
direct comparative studies in adults show that esomepra-
zole more effectively heals EE in adults than omeprazole
[8,9], lansoprazole [10,11], and pantoprazole [12]; how-
ever, similar studies have not been conducted in pediatric
populations. In this report, we describe the healing of EE
after esomeprazole treatment in children aged 1-11 years.
Although not a planned objective, this study allowed
assessment of the usefulness of an adult classification sys-
tem for EE in the pediatric population, the Los Angeles
(LA) Classification System. In addition, because the liter-
ature lacks reports of histologic data from young children
with GERD, baseline histology findings are reported here.
The pharmacokinetic profile of esomeprazole in children
aged 1-11 years has been published previously [13]. The
primary safety and clinical outcomes of esomeprazole
treatment of GERD from this study have been reported
previously [14].
Methods
Study design and patients
The study design, methodology, eligibility criteria, patient
characteristics, and safety assessments have been
described in detail previously [14]. Children aged 1-11
years with endoscopically confirmed GERD (determined
by endoscopy with or without biopsies) were screened
and eligible to be enrolled in an international, multi-
center, randomized, parallel-group, double-blind (for
dose) study evaluating once-daily esomeprazole during 8
weeks of treatment. Patients with allergic or eosinophilic
esophagitis, gastric ulcers, bleeding lesions, strictures,
and Barrett's esophagus were excluded from the study.
Erosive or histologic GERD was documented; however,
EE was not required. Endoscopic findings were classified
using the LA Classification System for EE (Table 1) [15].
As described in the literature [14], macroscopic evidence
for GERD seen on endoscopy was documented and
included hyperemia, ulcers, and nodularity. Patients with
no visible or definitive lesions underwent a mucosal
biopsy during baseline endoscopy for histologic confir-
mation of reflux esophagitis. Valid pediatric indicators of
histologic reflux esophagitis were recorded, including the
presence of intraepithelial eosinophils or neutrophils and
increased basal cell layer thickness and papillary height
[16,17]. Criteria for establishing and documenting a clini-
cal diagnosis of GERD were consistent with the
NASPGHAN guidelines [4].
Patients were assigned randomly to esomeprazole
(Nexium®; AstraZeneca LP, Wilmington, DE) 5 or 10 mg
(children ≥ 8 kg and < 20 kg) or 10 or 20 mg (children ≥ 20
kg) once daily for 8 weeks. For children aged < 6 years or
for those who had difficulty swallowing the capsules, cap-
sule contents could be mixed with 1 tablespoon of apple-
sauce. Age-appropriate liquid antacid medication,
MAALOX®  (aluminum hydroxide 225 mg/magnesium
hydroxide 200 mg per 5 mL; Novartis Consumer, Parsip-
pany, NJ) or equivalent, was allowed as rescue medica-
tion. Parents or guardians were instructed to administer
rescue medication according to product labeling or as
prescribed by the physician. Rescue medication use was
recorded; when applicable, use in excess of the prescribed
amount was reviewed with the parent or guardian at each
visit and documented.
Institutional Review Boards at each participating center
approved the study protocol (AstraZeneca study code
D9614C00097; ClinicalTrials.gov identifier
NCT00228527), and each patient's parent or guardian
provided written informed consent with assent from the
patient, where applicable, before any study-specific pro-
cedure was performed. Study procedures were conducted
in accordance with the ethical principles of the Declara-
tion of Helsinki and its amendments and with the Inter-
national Conference on Harmonization and Good
Clinical Practice guidelines.
Table 1: Los Angeles Classification System for erosive 
esophagitis 
LA grade Description
A ≥1 Mucosal break ≤5 mm 
that does not extend 
between the tops of two 
mucosal folds
B ≥1 Mucosal break ≥5 mm 
long that does not extend 
between the tops of two 
mucosal folds
C≥ 1  M u c o s a l  b r e a k  t h a t  i s  
continuous between the tops 
of two or more mucosal folds 
but that involves < 75% of 
the esophageal 
circumference
D≥ 1  M u c o s a l  b r e a k ,  w h i c h  
involves ≥75% of the 
esophageal circumference
LA: Los Angeles.Tolia et al. BMC Pediatrics 2010, 10:41
http://www.biomedcentral.com/1471-2431/10/41
Page 3 of 9
Assessments
All procedures including upper endoscopic evaluation
were indicated clinically and represented standard prac-
tice at the local institution. Accordingly, no patient
underwent endoscopy solely for study enrollment or
other research purposes. An upper gastrointestinal
endoscopy was performed during screening at the discre-
tion of the investigator. Patients who had a previous
endoscopic diagnosis of EE within 2 weeks of screening
and were candidates for PPI therapy were not required to
have an additional endoscopy if a full endoscopic report
with photographic documentation was available. Histo-
logic evidence was required for patients who were newly
diagnosed with GERD if the patient did not have EE to
confirm the presence of esophagitis. Endoscopy with
biopsy was used to document the extent of EE, determine
the presence of Helicobacter pylori, and rule out certain
exclusionary conditions. For patients who had EE at base-
line, a repeat endoscopy was planned after 8 weeks of
esomeprazole treatment to document healing. GERD-
related symptoms were reported by the parents or guard-
i a n s  o n  b e h a l f  o f  t h e  p a t i e n t s .  T h e s e  s y m p t o m s  w e r e
derived from the NASPGHAN guidelines [4] and
included heartburn (burning feeling rising from the
stomach or lower part of the chest toward the neck), acid
regurgitation (perception of unpleasant-tasting fluid
backing up into the throat and/or mouth), epigastric pain
(perception of discomfort located in the central upper
portion of the abdomen), vomiting (gastric contents are
forced up to and out of the mouth), difficulty swallowing
(difficulty passing anything through the pharynx or
esophagus), and feeding difficulties (food refusal, choking
with food/drink, and/or poor weight gain).
The LA Classification System was used to grade EE
(Table 1) [15]. Other pediatric endoscopic GERD descrip-
tors of esophagitis as reported in the literature were
accepted, and appropriate histologic confirmation was
obtained when indicated [18,19]. Per routine standards of
pediatric medical practice [20], mucosal biopsy speci-
mens were obtained during baseline endoscopy for histo-
logic confirmation of GERD-related esophagitis in
patients without visible or definitive lesions [21]. If
needed, biopsy specimens were recommended to be
taken from the distal esophagus, approximately 0.5 cm
above the Z-line (squamocolumnar junction) based on
the investigator's assessment of landmarks, and from any
area with an abnormal appearance. Biopsy was optional
for patients with endoscopically visible lesions, and speci-
mens were obtained for medical reasons only at the dis-
cretion of the investigator. Biopsy specimens were
evaluated at each study site for histologic findings,
including the number of intraepithelial eosinophils and
neutrophils [4,22,23], lymphocytes per high power field,
elongated length of papillae (> 50% to 75% of epithelial
thickness) [4,21,22], increased thickness of the basal cell
layer (> 20% to 25% of total epithelial thickness) [4,21,22],
and increased total epithelial thickness. Histologic
changes were recorded [24-26] but not required as a
research procedure. Histologic changes were character-
ized based on the standards from each pathologist's indi-
vidual institution; findings were recorded on the case
report form (e.g., those listed previously in Methods).
Safety was assessed by adverse events (AEs) spontane-
ously reported by the parent or guardian, reported in
response to an open question from the investigator, or
revealed by observation or change from baseline condi-
tions or values in medical histories, physical examina-
tions, vital signs, and clinical laboratory evaluations.
Statistical analysis
Outcome analyses of EE healing were conducted on the
intention-to-treat (ITT) population dataset. The ITT
population was defined as all patients who had baseline
and one or more postbaseline measurements, one or
more ingested doses of study medication, and completion
of a posttreatment endoscopy. EE was considered healed
if no signs of erosion were observed on final endoscopy.
The percentage of patients with healed esophageal ero-
sions and the 95% confidence interval for the total were
calculated by AstraZeneca (B.T.). The International Con-
ference on Harmonization guideline E1 recommends
randomization of ≥ 100 patients for the safety database of
any drug. Therefore, the study was designed to random-
ize ≥ 100 patients to ensure that ≥ 40 patients in each age
group would complete the study.
Results
Patient characteristics
The study was conducted between October 2004 and
November 2005 at 24 sites within Belgium (three sites),
France (two sites), Italy (four sites), and the United States
(15 sites). A total of 109 patients were randomized in the
study and included in the ITT population. Of the 49
patients who failed the screening process, four had
eosinophilic esophagitis, 27 had no endoscopic proof of
reflux esophagitis, two had a normal endoscopy, and 16
were not related to endoscopy (Figure 1). Baseline demo-
graphic and nonphysical disease characteristics were sim-
ilar across all treatment groups (Table 2). Fifty-two
patients (47.7%) were aged 1-5 years, and 57 (52.3%) were
aged 6-11 years. The mean age was 5.7 years. Height,
weight, and body mass index also were similar across
dose groups within each weight stratum (< 20 kg or ≥ 20
kg). Esomeprazole doses ranged 0.2-1.0 mg/kg. The most
common presenting GERD symptoms at baseline were
heartburn (52%), acid regurgitation (55%), and epigastric
pain (55%) (Table 2). The distribution of patients met the
study goal of ≥ 40 evaluable patients in each age group.Tolia et al. BMC Pediatrics 2010, 10:41
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Of 109 patients randomized, 53 (49%) had EE at base-
line and 56 (51%) had reflux esophagitis without EE
(Table 3). Of 83 patients enrolled from study sites within
the United States, 36 (43%) had EE; of 26 patients
enrolled from European sites, 17 (65%) had EE. The pro-
portion of patients with EE and other reflux esophagitis
was distributed evenly across treatment groups. All but
two patients had LA grades A or B EE (Table 3); one
patient had grade C (< 20 kg/10-mg group), and the other
had grade D (≥ 20 kg/20-mg group) [14]. Hiatal hernia
was documented in seven children in the < 20-kg group
and 12 children in the ≥ 20-kg group. Other esophageal
abnormalities (e.g., hyperemia, esophageal ulcers, nodu-
larity, prolapse gastropathy) were present in 55 children
(n = 21, < 20 kg; n = 34, ≥ 20 kg) (Table 3). Of 109 patients
in the ITT population, 107 had a biopsy. Investigators
reported other gastric and duodenal abnormalities when
detected. Other histologic findings were present in the
esophagus at baseline (Table 4). Dilation of intercellular
space was reported in 24% of patients.
Esophageal healing
Of 53 patients with EE at baseline, eight did not undergo
final endoscopies or were otherwise excluded from the
ITT population because of premature study discontinua-
tion (n = 4), revised diagnosis (n = 2), endoscopy per-
formed outside the study timeframe (n = 1), or failure to
give reason for not performing endoscopy (n = 1). Of 45
patients who had EE at baseline and underwent posttreat-
ment endoscopy, EE was healed in 40 patients (89%) (Fig-
ure 2). Healing rates were similar across all esomeprazole
dose groups. Healing of EE did not occur in five patients
(11%): two patients in the 20-mg group were rated as
improved but not completely healed (i.e., ≥ 1 LA grade
improvement), and three patients in the 10-mg groups
exhibited no change from baseline (n = 2, < 20 kg; n = 1, ≥
20 kg). Patients whose EE was not healed received doses
in the range of 0.17-0.66 mg/kg.
Adverse events
Safety data were evaluable in 108 of 109 patients random-
ized and are described in detail elsewhere [14]. In brief,
13 AEs considered by the investigator to be related to
esomeprazole treatment occurred in 10 of 108 patients
(9.3%). The most commonly reported treatment-related
AEs were diarrhea (2.8%; n = 3, 10-mg/< 20 kg group),
headache (1.9%; n = 2, 10-mg/≥ 20 kg group), and somno-
lence (1.9%; n = 1, 5-mg/< 20 kg group and n = 1, 10-mg/
< 20 kg group).
Discussion
Based on this study, the use of esomeprazole across a
wide dose range (0.2-1.0 mg/kg) daily for ≤ 8 weeks
resulted in significant healing of macroscopic and histo-
logic esophagitis in children aged 1-11 years. Few studies
of PPI treatment of young children with GERD, including
those with EE, are available [27-34]. The results of the
present study provide additional evidence to support the
safe use and tolerability of PPIs in children with GERD
with or without EE [4].
Moreover, to our knowledge, this study is the first to
prospectively report the use of the LA Classification Sys-
tem [15] to diagnose and document EE healing in young
children. Several EE classification systems exist in the
adult literature (e.g., Hetzel-Dent or Savary-Miller classi-
fications), which have been adapted previously for pediat-
ric studies [31,32]. Our results demonstrate that the LA
Classification System can be used successfully to classify
the severity of EE in children. The majority of children
with EE in this study had LA grades A and B (29% and
17%, respectively). The LA classification system offered a
simple, straightforward method to grade EE and docu-
ment healing in the absence of erosions. The use of the
LA classification system in children may allow for com-
parison between pediatric and adult data to unify our
knowledge of healing of EE; however, it has not been vali-
dated yet for use in pediatric populations.
The doses used in this study were determined from the
results of a pharmacokinetic study of esomeprazole in
children aged 1-11 years, an extrapolation of the recom-
mended adult esomeprazole doses using an exposure-
response relationship reported previously [13], and the
assumption that most children < 12 years weigh 8-60 kg.
For ethical reasons in a population of children with con-
firmed GERD, this study did not include a placebo con-
trol group but was double blind to dosage. The lack of a
control group is a potential limitation to this study. Fur-
thermore, the assessment of the clinical outcome of EE
was not controlled and was not the primary end point of
the study; however, more importantly, the clinical benefit
of esomeprazole in healing EE was documented. In addi-
tion, the small number of patients in each treatment
group precluded a comparison between doses.
Figure 1 Patient disposition. EE: erosive esophagitis.
158 Patients screened for eligibility
• Did not have endoscopic proof 
of reflux esophagitis, n = 27
• Presence of eosinophilic 
esophagitis, n = 4
• Had normal endoscopy, n = 2
• Failed for reasons unrelated 
to endoscopy, n = 16
109 Randomized
53 Patients had EE 56 Patients did not have EETolia et al. BMC Pediatrics 2010, 10:41
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Table 2: Demographic and baseline disease characteristics of all patients enrolled (N = 109)
Children < 20 kg Children ≥ 20 kg
Characteristic Esomeprazole
5 mg
(0.3-0.6 mg/kg)
(n = 26)
Esomeprazole
10 mg
(0.6-1.0 mg/kg)
(n = 23)
Esomeprazole
10 mg
(0.2-0.5 mg/kg)
(n = 31)
Esomeprazole
20 mg
(0.3-1.0 mg/kg)
(n = 29)
Girls, n (%) 14 (53.8) 14 (60.9) 14 (45.2) 11 (37.9)
Mean age, years 2.1 2.5 8.5 8.3
Age in years, n (%)
1 12 (46.2) 8 (34.8)
2 6 (23.1) 5 (21.7)
3 4 (15.4) 4 (17.4)
4 2 (7.7) 3 (13.0) 1 (3.2) 2 (6.9)
5 1 (3.8) 2 (8.7) 1 (3.2) 1 (3.4)
6 1 (3.8) 1 (4.3) 2 (6.5) 0
7 5 (16.1) 3 (10.3)
8 5 (16.1) 9 (31.0)
9 8 (25.8) 6 (20.7)
10 3 (9.7) 6 (20.7)
11 6 (19.4) 2 (6.9)
Race, n (%)
White 19 (73.1) 19 (82.6) 26 (83.9) 25 (86.2)
Black 7 (26.9) 4 (17.4) 5 (16.1) 3 (10.3)
Other 0 0 0 1 (3.4)
Mean height (range), cm 90.0 (70-109) 94.2 (80-119) 134.5 (108-168) 134.5 (112-159)
Mean weight (range), kg 12.8 (8-18) 14.1 (10-18) 35.5 (20-58) 34.5 (21-60)
Mean body mass index (SD), kg/m2 15.7 (2.1) 15.9 (1.7) 19.3 (4.8) 18.6 (3.9)
Helicobacter pylori-positive, n (%) 0 1 (4.3) 0 0
Symptoms at baseline, n (%)
Heartburn 15 (57.7) 10 (43.5) 19 (61.3) 13 (44.8)
Acid regurgitation 18 (69.2) 11 (47.8) 20 (64.5) 11 (37.9)
Epigastric pain 17 (65.4) 13 (56.5) 15 (48.4) 15 (51.7)
Vomiting 13 (50.0) 7 (30.4) 3 (9.7) 5 (17.2)
Eating difficulties 15 (57.7) 13 (56.5) 9 (29.0) 7 (24.1)
Difficulty swallowing 6 (23.1) 8 (34.8) 5 (16.1) 6 (20.1)
Extraesophageal symptoms at baseline, n (%) n = 12 n = 12 n = 16 n = 13
Hoarseness 4 (33.3) 4 (50.0) 4 (25.0) 7 (53.8)
Coughing 8 (66.7) 9 (75.0) 7 (43.8) 7 (53.8)
Gagging 5 (41.7) 6 (50.0) 2 (12.5) 4 (30.8)
Wheezing/stridor 1 (8.3) 1 (8.3) 2 (12.5) 0 (0)
Mean (range) esomeprazole dose, mg/kg 0.4 (0.3-0.6) 0.7 (0.6-1.0) 0.3 (0.2-0.5) 0.6 (0.3-1.0)Tolia et al. BMC Pediatrics 2010, 10:41
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In the present study, the prevalence of EE (49%) in chil-
dren aged 1-11 years was higher than that reported previ-
ously in children (12.4%) [3]. Baseline endoscopic and
histologic data showed that 18% of patients had esopha-
geal nodules, which have been shown to be a possible
predictor of EE in the PEDS-CORI [18]. Our results sug-
gest that dilation of intercellular space may be a potential
histologic diagnostic criterion for EE [6]. Dilation of
intercellular space was reported in 24% of the patients in
this study (reporting this information was not manda-
tory), whereas 49% of patients had endoscopically con-
firmed EE. Although these potential histologic predictors
of EE were identified in patients in this study, we cannot
determine accurately the incidence of these potential
markers because not every patient was evaluated for
these histologic changes in a standardized manner.
Determination of the true incidence of these markers in
children is an area of future research. Large epidemio-
logic studies in children also are needed to determine the
role of extraesophageal symptoms and concomitant con-
ditions (e.g., asthma) in GERD.
The criteria for establishing and documenting endo-
scopically proven GERD for study entry were consistent
with those previously recommended by NASPGHAN
[ 4 , 2 0 ] .  E n d o s c o p i c  f i n d i n g s  w e r e  r e q u i r e d  t o  b e  d o c u -
mented at study entry to allow for full characterization of
the extent of GERD, including the presence and severity
of EE and other gross findings. Furthermore, histologic
assessment, when available, aided in excluding the diag-
nosis of other esophageal disorders, such as eosinophilic
esophagitis. Although biopsy specimens were not evalu-
ated by a central reader and therefore were not standard-
ized, the histopathologic data obtained contribute to the
existing sparse literature in this patient population. Addi-
tionally, the reason for a greater proportion of patients
with EE in the European study sites compared with the
United States study sites is not clear. The reasons for such
geographic variation need to be studied further.
In this pediatric population, the clinical course and
manifestations of the spectrum of GERD symptoms
appear to be similar to those seen in adults. The current
study continues to expand on the knowledge and poten-
tial management options that are available for young chil-
dren with GERD and EE, and adult efficacy data may be
extrapolated to this age group [3,4,35-37]. An 8-week
treatment duration represents the approximate time
needed for healing of EE in adults [8-12]. Guidelines for
treatment of pediatric GERD recommend a 3-month
course of acid suppression treatment for children who
have GERD symptoms [4]. The results of the present
study parallel the results from those of previous studies of
PPIs in adults with EE and provide additional support for
the use of esomeprazole treatment for EE in young chil-
dren.
Conclusion
The findings of this study showed that an 8-week course
of esomeprazole treatment (0.2-1.0 mg/kg) healed esoph-
Table 3: Endoscopic findings at baseline, n (%)
Children < 20 kg Children ≥20 kg
Category Esomeprazole
5 mg
(0.3-0.6 mg/kg)
(n = 26)
Esomeprazole 
10 mg
(0.6-1.0 mg/kg)
(n = 23)
Esomeprazole 
10 mg
(0.2-0.5 mg/kg)
(n = 31)
Esomeprazole 
20 mg
(0.3-1.0 mg/kg)
(n = 29)
Total
(N = 109)
Other reflux 
esophagitis
14 (54) 11 (48) 15 (48) 16 (55) 56 (52)
Erosive 
esophagitis
12 (46) 12 (52) 16 (52) 13 (45) 53 (49)
LA grade A 6 (23) 6 (26) 11 (36) 9 (31) 32 (29)
LA grade B 6 (23) 5 (22) 5 (16) 3 (10) 19 (17)
LA grade C 0 1 (4) 0 0 1 (1)
LA grade D 0 0 0 1 (3) 1 (1)
Hiatal hernia 4 (15) 3 (13) 8 (26) 4 (14) 19 (17)
Other 
abnormality*
11 (42) 10 (44) 16 (52) 18 (62) 55 (50)
*Abnormalities occurring in ≥4 patients were nodularity (n = 20 [18%]), erythema/hyperemia (n = 23 [21%]), edema (n = 11 [10%]), prominent 
esophageal folds (n = 11 [10%]), and friability (n = 4 [4%]).
LA: Los Angeles.Tolia et al. BMC Pediatrics 2010, 10:41
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ageal erosions in 89% of children aged 1-11 years who had
EE. Although the LA Classification System was used suc-
cessfully to grade EE in this study, the development of a
new pediatric-specific scoring system is suggested. For
example, a complementary scoring system is needed to
accommodate other pediatric endoscopic findings
described in the literature, such as esophageal nodules
[18]. Histologic assessment showed frequent mucosal
damage in this population and provides further support
for the use of histology to augment endoscopic findings
in pediatric patients with GERD.
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Table 4: Baseline histologic data of the esophagus, n (%)*
Children < 20 kg Children ≥20 kg
Category Esomeprazole
5 mg
(0.3-0.6 mg/kg)
(n = 26)
Esomeprazole 
10 mg
(0.6-1.0 mg/kg)
(n = 23)
Esomeprazole 
10 mg
(0.2-0.5 mg/kg)
(n = 31)
Esomeprazole 
20 mg
(0.3-1.0 mg/kg)
(n = 29)
Total
(N = 109)
Eosinophilic densification 4 (15) 3 (13) 8 (26) 12 (41) 27 (25)
Intraepithelial eosinophils† 5 (19) 9 (39) 13 (42) 13 (45) 40 (37)
Intraepithelial neutrophils† 5 (19) 1 (4) 6 (19) 3 (10) 15 (14)
Intraepithelial 
lymphocytes†
13 (50) 9 (39) 17 (55) 14 (48) 53 (49)
Elongated length of 
papillae
16 (62) 10 (44) 16 (52) 19 (66) 61 (56)
Increased thickness of basal 
cell layer
15 (58) 13 (56) 15 (48) 19 (66) 62 (57)
Increased total epithelial 
thickness
11 (42) 10 (44) 10 (32) 10 (34) 41 (38)
Dilation of intercellular 
spaces
Absent/NR 21 (81) 21 (91) 24 (77) 17 (59) 83 (76)
< 25% 3 (12) 2 (9) 5 (16) 10 (34) 20 (18)
≥25% 2 (8) 0 2 (6) 2 (7) 6 (6)
Columnar epithelium
Present 4 (15) 4 (17) 3 (10) 4 (14) 15 (14)
Not
assessable
1 (4) 5 (22) 7 (23) 4 (14) 17 (16)
Cardia mucosa 2 (8) 3 (13) 1 (3) 4 (14) 10 (9)
Corpus mucosa 1 (4) 1 (4) 3 (10) 1 (3) 6 (6)
Diagnosis of microscopic 
reflux esophagitis
20 (77) 18 (78) 24 (77) 24 (83) 86 (79)
*107 Patients had a biopsy.
†Per high power field.
NR: not reported.Tolia et al. BMC Pediatrics 2010, 10:41
http://www.biomedcentral.com/1471-2431/10/41
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tual content. MI made substantial contributions to conception and design,
acquisition of data, and analysis and interpretation of data and was involved in
revising the manuscript for important intellectual content. All authors read and
approved the final manuscript.
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